David A. Liebner

David A. Liebner conducts clinical research on sarcomas (cancers of soft tissue, bone, and connective tissue) and related rare tumors, including gastrointestinal stromal tumors (GIST) and desmoid tumors. Much of his work involves early- and late-phase clinical trials testing new drug and cell-based therapies, including engineered T-cell therapies that use the immune system to target tumor cells, as well as contributing to national treatment guidelines for these cancers.​ His research combines patient-facing clinical trial leadership with biomarker studies aimed at understanding which patients respond to specific treatments.

Publication output has grown somewhat unevenly over the last decade, rising from single digits in 2017 to a peak of 13 in both 2020 and 2026, with continued strong activity in recent years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026